David I Watkins
Overview
Explore the profile of David I Watkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
8220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosen B, Sawatzki K, Ricciardi M, Smith E, Golez I, Mauter J, et al.
Front Immunol
. 2024 Nov;
15:1478063.
PMID: 39502699
Introduction: Spontaneous control of chronic-phase HIV/SIV viremia is often associated with the expression of specific MHC class I allotypes. HIV/SIV-specific CD8+ cytotoxic T lymphocytes (CTLs) restricted by these MHC class...
2.
Munt J, Henein S, Adams C, Young E, Hou Y, Conrad H, et al.
Cell Host Microbe
. 2023 Nov;
31(11):1850-1865.e5.
PMID: 37909048
The envelope (E) glycoprotein is the primary target of type-specific (TS) neutralizing antibodies (nAbs) after infection with any of the four distinct dengue virus serotypes (DENV1-4). nAbs can be elicited...
3.
Ricciardi M, Rust L, Pedreno-Lopez N, Yusova S, Biswas S, Webb G, et al.
Sci Transl Med
. 2023 Mar;
15(689):eade5795.
PMID: 36989376
Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine...
4.
Zhao F, Berndsen Z, Pedreno-Lopez N, Burns A, Allen J, Barman S, et al.
Nat Commun
. 2022 Sep;
13(1):5236.
PMID: 36068229
SIVmac239 infection of macaques is a favored model of human HIV infection. However, the SIVmac239 envelope (Env) trimer structure, glycan occupancy, and the targets and ability of neutralizing antibodies (nAbs)...
5.
Silveira C, Magnani D, Costa P, Avelino-Silva V, Ricciardi M, Timenetsky M, et al.
Front Immunol
. 2022 Jul;
13:908398.
PMID: 35837409
An effective vaccine against the dengue virus (DENV) should induce a balanced, long-lasting antibody (Ab) response against all four viral serotypes. The burst of plasmablasts in the peripheral blood after...
6.
Ishii H, Terahara K, Nomura T, Okazaki M, Yamamoto H, Shu T, et al.
Mol Ther
. 2022 Mar;
30(5):2048-2057.
PMID: 35231604
Effective T cell induction is an important strategy in HIV-vaccine development. However, it has been indicated that vaccine-induced HIV-specific CD4 T cells, the preferential targets of HIV infection, might increase...
7.
Haslwanter D, Lasso G, Wec A, Furtado N, Raphael L, Tse A, et al.
Cell Host Microbe
. 2022 Jan;
30(2):248-259.e6.
PMID: 34998466
The resurgence of yellow fever in South America has prompted vaccination against the etiologic agent, yellow fever virus (YFV). Current vaccines are based on a live-attenuated YF-17D virus derived from...
8.
Castro I, Ricciardi M, Gonzalez-Nieto L, Rakasz E, Lifson J, Desrosiers R, et al.
J Virol
. 2021 Apr;
95(14):e0033021.
PMID: 33910957
A prophylactic vaccine that confers durable protection against human immunodeficiency virus (HIV) would provide a valuable tool to prevent new HIV/AIDS cases. As herpesviruses establish lifelong infections that remain largely...
9.
Pedreno-Lopez N, Rosen B, Flores W, Gorman M, Voigt T, Ricciardi M, et al.
Front Immunol
. 2021 Apr;
12:657424.
PMID: 33796119
The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities...
10.
Martins M, Gonzalez-Nieto L, Ricciardi M, Bailey V, Dang C, Bischof G, et al.
J Virol
. 2020 Oct;
94(24).
PMID: 33028714
Given the complex biology of human immunodeficiency virus (HIV) and its remarkable capacity to evade host immune responses, HIV vaccine efficacy may benefit from the induction of both humoral and...